fda changes to tirzepatide Grants a New Indication for Obesity Management FDA Announces End To Compounded

Clinical trials have demonstrated significant reductions in hemoglobin A1c levels in patients with type 2 diabetes, as well as substantial weight loss in individuals treated for obesity

[ 9 , 10 ] These conflicting results highlight the uncertainty that persists in this area of research

Using Mounjaro as a first-line treatment for BED without addressing the psychological component sets up a pattern of medication dependence

It shifts the paradigm from treating the brain in isolation to treating the whole patient brain and body as an interconnected system

Daily pills seem easier to maintain long-term than weekly injections for some people, though others prefer the once-weekly approach